Read the news and go back reading the news, again. Market expected early halt of trial of COMET-1. The data are not there to support that decision so they must march on to fully COMPLETE the trial. Worst case scenario, the drug is not suitable for prostate but it may still be GOOD for rectal cancer and others. Hand it there, longies!